Oncotelic Therapeutics OTLC
OTC OTLC
$0.02 +0.00 (+0.00%)
At close: Oct 15, 2026 · 4:00 PM EDT

Oncotelic Therapeutics (OTLC) Net Margin (2012 - 2026)

Updated

Oncotelic Therapeutics' Net Margin came in at 155.26% for Q2 2026.

Analysis

Oncotelic Therapeutics (OTLC) Net Margin (2012 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Oncotelic Therapeutics reported Net Margin of 78120.89%; for FY2023, it came in at -11290.13%.

  • Net Margin carries a three-year change of -10744.27 percentage points (FY2020 to FY2023).
  • Going back by year, Net Margin was -1878.21% in FY2021 (-1332.35 pp) and -545.86% in FY2020.
  • The Q2 2026 figure represents the highest quarterly Net Margin since Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,109.83 Bn 1,078.42 Bn 19.71 Bn 30.88%
2 Johnson & Johnson 610.61 Bn 529.14 Bn 17.26 Bn 21.86%
3 AbbVie 500.66 Bn 473.77 Bn 12.70 Bn 21.27%
4 Merck 354.64 Bn 309.02 Bn 12.21 Bn -8.04%
5 Novartis Ag 291.14 Bn 255.13 Bn 11.24 Bn 22.65%
6 Astrazeneca 254.18 Bn 227.87 Bn 12.86 Bn 16.30%
7 Amgen 229.46 Bn 184.86 Bn 7.24 Bn 23.62%
8 Gilead Sciences 190.33 Bn 164.53 Bn 6.22 Bn -134.51%
9 Pfizer 167.92 Bn 114.57 Bn 10.94 Bn -1.65%
10 Oncotelic Therapeutics 8.28 Mn 7.42 Mn - 155.26%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 155.26%
Sep 30, 2023 164.73%
Mar 31, 2021 -560.62%
Jun 30, 2020 41.58%
Mar 31, 2020 -1,366.53%
Sep 30, 2013 -5,225.26%
Dec 31, 2012 -3,988.10%
Mar 31, 2012 -1,658.77%
API Access

Oncotelic Therapeutics Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=OTLC&period=max&api_key=YOUR_API_KEY